CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
Toviaz (Fesoterodine)drug
Likely dose
Toviaz (Fesoterodine) 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00605319
NCT00605319Phase 4Completed
CompareCT.gov

An Open Label Study to Measure the Efficacy of Fesoterodine (Toviaz) on Continued Detrusor Overactivity in Patients That Have Undergone Treatment for Bladder Outlet Obstruction

Weill Medical College of Cornell University·interventional·Posted Jan 31, 2008·Updated Apr 10, 2018

In Brief

A Phase 4 clinical trial evaluating Toviaz (Fesoterodine) for Bladder Outlet Obstruction. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Outlet Obstruction
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 31, 2008
Enrollment StartJan 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.4 years ago

Interventions

Toviaz (Fesoterodine)drug

4mg to 8mg by mouth once daily